Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia.
Castillo JJ, Branagan AR, Sermer D, Flynn CA, Meid K, Little M, Stockman K, White T, Canning A, Guerrera ML, Kofides A, Liu S, Liu X, Richardson K, Tsakmaklis N, Patterson CJ, Hunter ZR, Treon SP, Sarosiek S. Castillo JJ, et al. Among authors: sermer d. Blood. 2024 Feb 15;143(7):582-591. doi: 10.1182/blood.2023022420. Blood. 2024. PMID: 37971194 Free PMC article.
Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma.
Sermer D, Bobillo S, Dogan A, Zhang Y, Seshan V, Lavery JA, Batlevi C, Caron P, Hamilton A, Hamlin P, Horwitz S, Joffe E, Kumar A, Matasar M, Noy A, Owens C, Moskowitz A, Palomba ML, Straus D, von Keudell G, Rodriguez-Rivera I, Falchi L, Zelenetz A, Yahalom J, Younes A. Sermer D, et al. Blood Adv. 2020 Jul 28;4(14):3382-3390. doi: 10.1182/bloodadvances.2020001551. Blood Adv. 2020. PMID: 32722781 Free PMC article.
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era.
Bobillo S, Joffe E, Lavery JA, Sermer D, Ghione P, Noy A, Caron PC, Hamilton A, Hamlin PA, Horwitz SM, Kumar A, Matasar MJ, Moskowitz A, Owens CN, Palomba ML, Batlevi CL, Straus D, von Keudell G, Zelenetz AD, Yahalom J, Dogan A, Seshan VE, Younes A. Bobillo S, et al. Among authors: sermer d. Blood. 2021 Jan 7;137(1):39-48. doi: 10.1182/blood.2020005112. Blood. 2021. PMID: 32730585 Free PMC article.
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies.
Sermer D, Batlevi C, Palomba ML, Shah G, Lin RJ, Perales MA, Scordo M, Dahi P, Pennisi M, Afuye A, Silverberg ML, Ho C, Flynn J, Devlin S, Caron P, Hamilton A, Hamlin P, Horwitz S, Joffe E, Kumar A, Matasar M, Noy A, Owens C, Moskowitz A, Straus D, von Keudell G, Rodriguez-Rivera I, Falchi L, Zelenetz A, Yahalom J, Younes A, Sauter C. Sermer D, et al. Blood Adv. 2020 Oct 13;4(19):4669-4678. doi: 10.1182/bloodadvances.2020002118. Blood Adv. 2020. PMID: 33002134 Free PMC article.
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse.
Bobillo S, Joffe E, Sermer D, Mondello P, Ghione P, Caron PC, Hamilton A, Hamlin PA, Horwitz SM, Kumar A, Matasar MJ, Batlevi CL, Moskowitz A, Noy A, Owens CN, Palomba ML, Straus D, von Keudell G, Dogan A, Zelenetz AD, Seshan VE, Younes A. Bobillo S, et al. Among authors: sermer d. Blood Cancer J. 2021 Jun 16;11(6):113. doi: 10.1038/s41408-021-00506-3. Blood Cancer J. 2021. PMID: 34135307 Free PMC article.
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma.
Van Le H, Van Naarden Braun K, Nowakowski GS, Sermer D, Radford J, Townsend W, Ghesquieres H, Menne T, Porpaczy E, Fox CP, Schusterbauer C, Liu FF, Yue L, De Benedetti M, Hasskarl J. Van Le H, et al. Among authors: sermer d. Leuk Lymphoma. 2023 Mar;64(3):573-585. doi: 10.1080/10428194.2022.2160200. Epub 2023 Feb 8. Leuk Lymphoma. 2023. PMID: 36755418 Clinical Trial.
15 results